Literature DB >> 17089369

Insulin-based regimens decrease mortality rates in critically ill patients: a systematic review.

Jane Langley1, Gary Adams.   

Abstract

OBJECTIVES: To determine whether treatment with glucose-insulin-potassium (GIK), insulin and glucose, or insulin by itself is beneficial in limiting organ damage after acute myocardial infarction (AMI) and reducing mortality and morbidity among critically ill hyperglycaemic patients.
METHODS: Systematic review of randomized controlled trials. MAIN OUTCOME MEASURE: To assess whether tight glycaemic control reduces morbidity and mortality. STUDIES REVIEWED: Randomized controlled trials of insulin-based regimens in the treatment of critically ill patients.
RESULTS: Nine hundred and twenty-four potentially relevant studies were identified and screened for retrieval. Of these, 16 randomized controlled trials met the inclusion criteria (Table 1). Ten studies examined the effects of GIK, and six of these studies reported a mortality reduction with GIK treatment in addition to enhanced myocardial performance. Five studies examined the administration of insulin. Among these studies, tight glycaemic control of blood glucose in one study was shown to reduce morbidity and mortality of patients in intensive care. Only one study examined insulin/glucose therapy, and it showed a post-myocardial infarction mortality reduction of one year.
CONCLUSIONS: There is increasing evidence that maintaining normoglycaemia and treatment with insulin-based regimens is beneficial in limiting organ damage and significantly reduces both morbidity and mortality in critically ill patients who require intensive care therapy. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17089369     DOI: 10.1002/dmrr.696

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  12 in total

1.  The need for continuous blood glucose monitoring in the intensive care unit.

Authors:  Ram Weiss; Isaac Lazar
Journal:  J Diabetes Sci Technol       Date:  2007-05

2.  Technical challenges and clinical outcomes of using a closed-loop glycemic control system in the hospital.

Authors:  Takehiro Okabayashi; Akihito Kozuki; Tatsuaki Sumiyoshi; Yasuo Shima
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

Review 3.  Postinjury Inflammation and Organ Dysfunction.

Authors:  Angela Sauaia; Frederick A Moore; Ernest E Moore
Journal:  Crit Care Clin       Date:  2017-01       Impact factor: 3.598

4.  Insulin-Based Infusion System: Advancing the Development.

Authors:  Nasseh Hashemi; Tim Valk; Kim Houlind; Niels Ejskjaer
Journal:  J Diabetes Sci Technol       Date:  2019-03-10

5.  Therapy: Intensive glucose control in the ICU: is sugar nice?

Authors:  David B Sacks
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

6.  Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia.

Authors:  Eszter M Horváth; Rita Benko; Domonkos Gero; Levente Kiss; Csaba Szabó
Journal:  Life Sci       Date:  2007-11-21       Impact factor: 5.037

7.  Glucose-modulated tyrosine nitration in beta cells: targets and consequences.

Authors:  Thomas Koeck; John A Corbett; John W Crabb; Dennis J Stuehr; Kulwant S Aulak
Journal:  Arch Biochem Biophys       Date:  2009-04-15       Impact factor: 4.013

Review 8.  Glucose control in the ICU: is there a time for more ambitious targets again?

Authors:  Martin Haluzik; Milos Mraz; Petr Kopecky; Michal Lips; Stepan Svacina
Journal:  J Diabetes Sci Technol       Date:  2014-05-18

9.  Early versus late intravenous insulin administration in critically ill patients.

Authors:  Shyoko Honiden; Atara Schultz; Shelly A Im; David M Nierman; Michelle N Gong
Journal:  Intensive Care Med       Date:  2008-01-08       Impact factor: 17.440

10.  Predicting mortality of critically ill patients by blood glucose levels.

Authors:  Byung Sam Park; Ji Sung Yoon; Jun Sung Moon; Kyu Chang Won; Hyoung Woo Lee
Journal:  Diabetes Metab J       Date:  2013-10-17       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.